

10/561969

[REDACTED] PCT/US 22 DEC 2005

USPTO Form 1449 U.S. Department of Commerce
 Patent and Trademark Office
 INFORMATION DISCLOSURE
 CITATION
 Sheet 1 of 1

Attorney Docket No.
010180.00047Serial No.
TBA

Applicant(s): Kwai Ming CHEUNG et al

Filing Date: Herewith

Group: TBA

U.S. PATENT DOCUMENTS

Examiner Initial	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
/Y.C./	US 5 869 509 A	9 February 1999	Gribkoff Valentin K et al			
/Y.C./	US 5 489 598 A	6 February 1996	Connor David T. et al			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document No.	Date	Country	Class	Subclass	Translation	
						YES	NO
*	WO 01/34580 A	17 May 2001	PCT			ABS	
	DE 43 20 801 A	5 January 1995	GERMANY			ABS	
	EP 1 293 503 A	19 March 2003	EUROPE			ABS	
	EP 1 070 708 A	24 January 2001	EUROPE			ABS	
	WO 99/64415 A	16 December 1999	PCT			ABS	
	WO 03/015777 A	27 February 2003	PCT			ABS	
	FR 2 258 180 A	18 August 1975	FRANCE			ABS	
	GB 1 406 345 A	17 September 1975	GREAT BRITAIN				
	WO 01/34198 A	17 May 2001	PCT				
	WO 99/40088 A	12 August 1999	PCT			ABS	
	WO 01/07436 A	1 February 2001	PCT			ABS	
	WO 03/101985 A	11 December 2003	PCT			ABS	
	WO 03/104207 A	18 December 2003	PCT			ABS	
*	WO 2004/030611 A	15 April 2004	PCT			ABS	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

* FEVIG JOHN M ET AL: "Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 5, 12 March 2001, XP002301746, ISSN: 0960-894X

EXAMINER /Yong Chu/

DATE CONSIDERED

10/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* The references are not considered, because they are not provided to the Examiner.